Beovu Lawsuit

Shortly after introducing the wet-age related macular degeneration (AMD) treatment Beovu, side effects were linked to reports of severe and potentially blinding vision problems. As a result, new warnings about this risk were added in June 2020.

STATUS OF BEOVU LAWSUITS: A limited group of users who received an injection for treatment of AMD between October 2019 and July 2020 may be entitled to financial compensation through a Beovu lawsuit.

Lawyers are reviewing cases for users who experienced:

Learn More About

Beovu Lawsuits

Side effects of Beovu have been linked to reports of severe and permanent vision problems, known as retinal vasculitis.

  • Retinal Vasculitis
  • Retinal Vascular Occlusion
  • Blurry Vision, Floaters or Other Complications



OVERVIEW: Beovu (brolucizumab) was approved by the FDA on October 7, 2019, as an injection treatment for wet age-related macular degeneration (AMD). It is part of a class of drugs known as anti-vascular endothelial growth factor therapy, or anti-VEGF. However, similar vision problems have not been linked to other medications in this class.

Within a few months after Beovu was introduced, eye specialists noted a number of concerning Beovu eye problems, involving serious inflammation of the vascular branches of the retinal artery, known as retinal vasculitis, which can result in symptoms like:

  • Blurry Vision
  • Visual Floaters
  • Dark Spots in Vision
  • Difficulty Distinguishing Colors
  • Distorted Images

BEOVU VISION WARNINGS: In February 2020, the American Society of Retina Specialists (ASRS) issued warnings to its members about the link between Beovu and eye inflammation.

The group indicated that it was aware of at least 14 cases of retinal vasculitis following Beovu injections, including at least 11 cases that resulted in a retinal vascular occlusion, which occurs when the vein becomes blocked. This can cause a complete loss of vision and blindness if permanent damage is suffered by the retina.

On June 11, 2020, the FDA announced new Beovu warning label information, which highlights the risk of retinal vasculitis and retinal vascular occlusion following an injection. Doctors were urged to instruct patients to report any change in vision from Beovu without delay.

BEOVU LAWYERS REVIEWING CLAIMS: If earlier information had been provided to users about the potential Beovu side effects, many individuals who received the injection shortly after it was introduced may have avoided permanent vision problems.

Evidence suggests that Novartis knew or should have known about the vision risks associated with Beovu, yet placed its desire for profits before consumer safety by withholding important warnings that would have negatively impacted sales. As a result, Beovu lawyers are reviewing potential claims for individuals who received this injection prior to June 11, 2020 and experienced problems.


Share Your Story With Our Community

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Leadership Development Committee for Suboxone Dental Injury Lawyers Established in Federal MDL
Leadership Development Committee for Suboxone Dental Injury Lawyers Established in Federal MDL (Posted yesterday)

The U.S. District Judge presiding over all Suboxone lawsuits has created a mentorship program to use the litigation to provide some attorneys an opportunity to gain experience in handling complex federal multidistrict litigations.

Gilead Settlement Resolves 2,625 HIV Drug Lawsuits Pending in Federal Courts for $40M
Gilead Settlement Resolves 2,625 HIV Drug Lawsuits Pending in Federal Courts for $40M (Posted 3 days ago)

Gilead says it will pay $40 million to resolve HIV drug lawsuits over Truvada, Atripla, Viread, Stribild and Complera pending in the federal court system, involving claims that the the company sat on safer formulations of the drugs for years to increase profits.